Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies
US8246958B2 · kind B2 · utility
53Cited by
5References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 17, 2008 |
| Grant date | Aug 21, 2012 |
| Priority date | — |
| Expiry date | Apr 10, 2029 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/7055
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.